Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026
Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Fineline Cube Jul 23, 2026
Company Drug

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Fineline Cube Jul 23, 2026
Company Drug

Tot Biopharmaceutical Terminates Phase III Study for HER2-Targeted ADC TAA013

Fineline Cube Mar 20, 2023

Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced the termination of the Phase III...

Company Drug

Shouyao Holdings Receives CDE Approval for Phase II Study of Third-Generation ALK Inhibitor

Fineline Cube Mar 20, 2023

Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received clinical...

Company Deals

Enlight Medical Technologies to Acquire Synexmed, Expand Vascular Intervention Capabilities

Fineline Cube Mar 20, 2023

China-based Enlight Medical Technologies (Shanghai) Co., Ltd is set to fully acquire Japanese firm Japan...

Company Drug

Likang Life Sciences’ Personalized Neoantigen Vaccine LK101 Receives IND Approval

Fineline Cube Mar 20, 2023

Likang Life Sciences has announced that it has received Investigational New Drug (IND) approval from...

Company Medical Device

AffaMed Technologies’ EDOF Intraocular Lenses Receive FDA Approval in Taiwan

Fineline Cube Mar 20, 2023

AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced that it...

Company Drug

Walvax Biotechnology Announces Positive Results for RQ3013 mRNA Vaccine

Fineline Cube Mar 20, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the safety, immunogenicity, and protective efficacy...

Company Drug

AIM Vaccine Initiates Phase I Clinical Study for MCV4 Meningococcal Vaccine in China

Fineline Cube Mar 17, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the initiation of a single-center, open...

Company Deals

Bochuang Biotechnology Secures Angel Funding for High-Purity Collagen and Innovative Medical Product Development

Fineline Cube Mar 17, 2023

Jiangsu Bochuang Biotechnology Co., Ltd reportedly secured an undisclosed amount of funding in an angel...

Company Drug

NMPA Accepts Market Filing for Guangdong Zhongsheng’s COVID-19 Drug RAY1216

Fineline Cube Mar 17, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that the market filing for...

Company Drug

Mabwell Bioscience’s 9MW3811 Gains NMPA Approval for Clinical Trials in China

Fineline Cube Mar 17, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...

Company Drug

Everest Medicines’ Xerava Receives NMPA Approval for Complicated Intra-Abdominal Infections

Fineline Cube Mar 17, 2023

China-based Everest Medicines Limited (HKG: 1952) has announced that it has received market approval from...

Company Deals

Terumo Blood and Cell Technologies Partners with EurekaBio to Establish Cell Therapy Lab

Fineline Cube Mar 17, 2023

US-based Terumo Blood and Cell Technologies has entered into a partnership with Shenzhen-headquartered EurekaBio Technology...

Policy / Regulatory

Beijing Initiates Volume-Based Procurement for Ophthalmology and Orthopedics Medical Consumables

Fineline Cube Mar 17, 2023

The Beijing Municipal Medical Insurance Bureau has released a notification regarding the volume-based procurement (VBP)...

Company Drug

Fosun Pharma’s Generic Remodulin Gains NMPA Approval for Pulmonary Arterial Hypertension

Fineline Cube Mar 17, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its generic...

Company Drug

RemeGen Gains NMPA Approval for Phase I/IIa Study of RC88 with Junshi Bio’s PD-1 Inhibitor

Fineline Cube Mar 17, 2023

China-based pharmaceutical firm RemeGen (HKG: 9995) has received approval from the National Medical Products Administration...

Company Deals

Triastek Partners with Boehringer Ingelheim to Advance 3D Printed Drug Dosage Forms

Fineline Cube Mar 17, 2023

China-based Triastek Inc., a leading pharmaceutical-focused 3D printing company, has entered into a partnership with...

Company Drug

ImmuneOnco Gains NMPA Approval for Phase Ib/II Study of IMM27M in Advanced Tumors

Fineline Cube Mar 16, 2023

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...

Company Deals

ArkBio and Calibr Renew Collaboration to Develop First-in-Class Respiratory Drug AK0705

Fineline Cube Mar 16, 2023

Shanghai Ark Biopharmaceutical Co., Ltd announced that it has renewed its co-development collaboration with Calibr,...

Company Medical Device

Agena Bioscience’s CYP2C19 Genotyping Kit Gains NMPA Approval for Cardiovascular Applications

Fineline Cube Mar 16, 2023

Shanghai-based Agena Bioscience announced that its human CYP2C19 genotyping test kit, co-developed with Simcere Pharmaceutical...

Company

Ping An Life Insurance Reports Steady Profit Growth and Expands Managed Care Services

Fineline Cube Mar 16, 2023

Ping An Life Insurance Company of China Ltd released its 2022 financial report, recording RMB...

Posts pagination

1 … 582 583 584 … 699

Recent updates

  • MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge
  • CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer
  • PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments
  • Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B
  • OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge

Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Company Drug

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Company Drug

Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.